Amgen gives first glimpse at PRMT5 inhibitor, days after Bristol Myers put a $1B promise on the targetnews2023-10-13T13:40:31+00:00October 13th, 2023|Endpoints News|
EU committee confirms negative opinion for Amylyx ALS drug, rejecting company appealnews2023-10-13T13:00:54+00:00October 13th, 2023|Endpoints News|
FDA approves etrasimod, Pfizer’s oral drug for ulcerative colitisnews2023-10-13T13:00:50+00:00October 13th, 2023|Endpoints News|
Cassava Sciences responds to accusations of ‘scientific misconduct’ by researcher at CUNYnews2023-10-13T11:25:06+00:00October 13th, 2023|Endpoints News|
Poseida promotes cell therapy president to CEO; After IPO, Neumora appoints R&D chiefnews2023-10-13T10:54:50+00:00October 13th, 2023|Endpoints News|
Santhera gears up for EU launch of vamorolone in Duchenne after positive CHMP opinionnews2023-10-13T10:00:05+00:00October 13th, 2023|Endpoints News|
Most detailed human brain map yet is ‘laying the foundation for finding future cures’news2023-10-12T19:35:57+00:00October 12th, 2023|Endpoints News|
Flagship Pioneering recasts its corporate brand with ‘Bigger Leaps’ tagline and ambitionnews2023-10-12T19:16:02+00:00October 12th, 2023|Endpoints News|
More than ‘just a rash’: Incyte taps Mandy Moore in atopic dermatitis campaignnews2023-10-12T17:58:00+00:00October 12th, 2023|Endpoints News|
Quality considerations for topical eye treatments: FDA publishes new draft guidancenews2023-10-12T17:47:18+00:00October 12th, 2023|Endpoints News|
